Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Biol Blood Marrow Transplant. 2014 Sep 30;21(2):373–378. doi: 10.1016/j.bbmt.2014.09.022

Figure 1. Association between number of induction courses and post-HCT outcome for AML patients in CR1.

Figure 1

Estimates of overall survival (A), relapse-free survival (B), cumulative incidence of relapse (C), and cumulative incidence of non-relapse mortality (D) following myeloablative allogeneic HCT for AML in complete morphologic remission, shown individually for patients who required 1 course (n=138; black, solid line), 2 courses (n=66; grey, solid line), or >2 courses (n=16; grey, dashed line) of induction therapy to achieve CR1.